|
|
| Line 162: |
Line 162: |
|
| |
|
| ==Individual Region Genomic Gain/Loss/LOH== | | ==Individual Region Genomic Gain/Loss/LOH== |
| Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene rearrangements. Details on clinical significance such as prognosis and other important information can be provided in the notes section. Can refer to CGC workgroup tables as linked on the homepage if applicable. Please include references throughout the table. Do not delete the table.'') </span>
| | None |
| {| class="wikitable sortable" | | {| class="wikitable sortable" |
| |- | | |- |
| Line 169: |
Line 169: |
| !'''Established Clinical Significance Per Guidelines - Yes or No (Source)''' | | !'''Established Clinical Significance Per Guidelines - Yes or No (Source)''' |
| !'''Clinical Relevance Details/Other Notes''' | | !'''Clinical Relevance Details/Other Notes''' |
| |-
| |
| |<span class="blue-text">EXAMPLE:</span>
| |
| 7
| |
| |<span class="blue-text">EXAMPLE:</span> Loss
| |
| |<span class="blue-text">EXAMPLE:</span>
| |
| chr7
| |
| |<span class="blue-text">EXAMPLE:</span>
| |
| Unknown
| |
| |<span class="blue-text">EXAMPLE:</span> D, P
| |
| |<span class="blue-text">EXAMPLE:</span> No
| |
| |<span class="blue-text">EXAMPLE:</span>
| |
| Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference). Monosomy 7/7q deletion is associated with a poor prognosis in AML (add references).
| |
| |-
| |
| |<span class="blue-text">EXAMPLE:</span>
| |
| 8
| |
| |<span class="blue-text">EXAMPLE:</span> Gain
| |
| |<span class="blue-text">EXAMPLE:</span>
| |
| chr8
| |
| |<span class="blue-text">EXAMPLE:</span>
| |
| Unknown
| |
| |<span class="blue-text">EXAMPLE:</span> D, P
| |
| |
| |
| |<span class="blue-text">EXAMPLE:</span>
| |
| Common recurrent secondary finding for t(8;21) (add references).
| |
| |-
| |
| |<span class="blue-text">EXAMPLE:</span>
| |
| 17
| |
| |<span class="blue-text">EXAMPLE:</span> Amp
| |
| |<span class="blue-text">EXAMPLE:</span>
| |
| 17q12; chr17:39,700,064-39,728,658 [hg38; 28.6 kb]
| |
| |<span class="blue-text">EXAMPLE:</span>
| |
| ''ERBB2''
| |
| |<span class="blue-text">EXAMPLE:</span> D, P, T
| |
| |
| |
| |<span class="blue-text">EXAMPLE:</span>
| |
| Amplification of ''ERBB2'' is associated with HER2 overexpression in HER2 positive breast cancer (add references). Add criteria for how amplification is defined.
| |
| |- | | |- |
| | | | | |
| Line 216: |
Line 180: |
|
| |
|
| ==Characteristic Chromosomal or Other Global Mutational Patterns== | | ==Characteristic Chromosomal or Other Global Mutational Patterns== |
| Put your text here and fill in the table <span style="color:#0070C0">(I''nstructions: Included in this category are alterations such as hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis; microsatellite instability; homologous recombination deficiency; mutational signature pattern; etc. Details on clinical significance such as prognosis and other important information can be provided in the notes section. Please include references throughout the table. Do not delete the table.'')</span>
| | None |
| {| class="wikitable sortable" | | {| class="wikitable sortable" |
| |- | | |- |
| Line 226: |
Line 190: |
| !'''Established Clinical Significance Per Guidelines - Yes or No (Source)''' | | !'''Established Clinical Significance Per Guidelines - Yes or No (Source)''' |
| !'''Clinical Relevance Details/Other Notes''' | | !'''Clinical Relevance Details/Other Notes''' |
| |-
| |
| |<span class="blue-text">EXAMPLE:</span>
| |
| Co-deletion of 1p and 18q
| |
| |<span class="blue-text">EXAMPLE:</span> See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).
| |
| |<span class="blue-text">EXAMPLE:</span> Common (Oligodendroglioma)
| |
| |<span class="blue-text">EXAMPLE:</span> D, P
| |
| |
| |
| |
| |
| |-
| |
| |<span class="blue-text">EXAMPLE:</span>
| |
| Microsatellite instability - hypermutated
| |
| |
| |
| |<span class="blue-text">EXAMPLE:</span> Common (Endometrial carcinoma)
| |
| |<span class="blue-text">EXAMPLE:</span> P, T
| |
| |
| |
| |
| |
| |- | | |- |
| | | | | |
